Chinese expert consensus on the risk assessment and management of panvascular disease inpatients with type 2 diabetes mellitus (2022 edition)

Panvascular disease is not only a common comorbidity of type 2 diabetes mellitus (T2DM) but also the leading cause of disability and death in T2DM patients. To promote multidisciplinary cooperation and integration for early detection of panvascular disease in patients with T2DM, a group of Chinese researchers in the fields of cardiovascular disease, endocrinology, nephrology, neurology, and health management led by the Chinese Society of Cardiology and Chinese Medical Association, formed a “Chinese Expert Consensus on Risk Assessment and Management of Panvascular Disease in Patients with Type 2 Diabetes” study group to review the latest evidence and major developments in relevant domestic and international disciplines to develop this consensus. The consensus covers the epidemiological characteristics, pathophysiological mechanisms, multidisciplinary collaborative treatments, and risk assessment and management of panvascular disease in patients with T2DM, with an emphasis on early-risk assessment of panvascular disease in patients with T2DM, including the assessment of risk factors, vascular structure and function, and target organ damage at least once a year. In addition, this consensus emphasized that managing panvascular disease in patients with T2DM requires the involvement of both patients and multidisciplinary physicians, and reinforces the importance of controlling blood glucose, blood pressure, and lipids and anti-platelet therapy in addition to lifestyle interventions. This consensus will help guide and assist clinicians regarding the standardized and comprehensive management of panvascular disease in patients with T2DM and improve patient prognosis.